Universal Biosensors Inc
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of… Read more
Universal Biosensors Inc (UBI) - Net Assets
Latest net assets as of June 2025: AU$7.08 Million AUD
Based on the latest financial reports, Universal Biosensors Inc (UBI) has net assets worth AU$7.08 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$14.94 Million) and total liabilities (AU$7.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$7.08 Million |
| % of Total Assets | 47.38% |
| Annual Growth Rate | 12.28% |
| 5-Year Change | -54.26% |
| 10-Year Change | 31.05% |
| Growth Volatility | 188.81 |
Universal Biosensors Inc - Net Assets Trend (2002–2024)
This chart illustrates how Universal Biosensors Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Universal Biosensors Inc (2002–2024)
The table below shows the annual net assets of Universal Biosensors Inc from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$17.37 Million | -10.95% |
| 2023-12-31 | AU$19.51 Million | -25.23% |
| 2022-12-31 | AU$26.09 Million | -5.49% |
| 2021-12-31 | AU$27.61 Million | -27.30% |
| 2020-12-31 | AU$37.98 Million | -16.34% |
| 2019-12-31 | AU$45.39 Million | -10.42% |
| 2018-12-31 | AU$50.67 Million | +296.84% |
| 2017-12-31 | AU$12.77 Million | -3.66% |
| 2016-12-31 | AU$13.25 Million | -0.01% |
| 2015-12-31 | AU$13.26 Million | -32.85% |
| 2014-12-31 | AU$19.74 Million | -33.50% |
| 2013-12-31 | AU$29.68 Million | -24.61% |
| 2012-12-31 | AU$39.37 Million | +12.42% |
| 2011-12-31 | AU$35.02 Million | -25.83% |
| 2010-12-31 | AU$47.22 Million | -7.98% |
| 2009-12-31 | AU$51.31 Million | +5.36% |
| 2008-12-31 | AU$48.70 Million | -18.93% |
| 2007-12-31 | AU$60.07 Million | +62.16% |
| 2006-12-31 | AU$37.05 Million | +841.95% |
| 2005-12-31 | AU$3.93 Million | -1.01% |
| 2004-12-31 | AU$3.97 Million | -2.46% |
| 2003-12-31 | AU$4.07 Million | +199.49% |
| 2002-12-31 | AU$1.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Universal Biosensors Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 222962.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$29.81K | 0.17% |
| Other Comprehensive Income | AU$-345.32K | -1.99% |
| Other Components | AU$131.35 Million | 756.11% |
| Total Equity | AU$17.37 Million | 100.00% |
Universal Biosensors Inc Competitors by Market Cap
The table below lists competitors of Universal Biosensors Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kancera AB (publ)
ST:KAN
|
$1.49 Million |
|
Forbidden Foods Ltd
AU:FFF
|
$1.49 Million |
|
Oscar Properties Holding AB
ST:OP
|
$1.49 Million |
|
Lord Resources Ltd
AU:LRD
|
$1.49 Million |
|
Asiabasemetals Inc
V:ABZ
|
$1.49 Million |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
$1.49 Million |
|
Alakasa Industrindo Tbk
JK:ALKA
|
$1.49 Million |
|
Mohit Industries Limited
NSE:MOHITIND
|
$1.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Universal Biosensors Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,507,809 to 17,371,433, a change of -2,136,376 (-11.0%).
- Net loss of 14,239,743 reduced equity.
- Share repurchases of 12,015,280 reduced equity.
- New share issuances of 12,015,280 increased equity.
- Other comprehensive income decreased equity by 13,155.
- Other factors increased equity by 12,116,522.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-14.24 Million | -81.97% |
| Share Repurchases | AU$12.02 Million | -69.17% |
| Share Issuances | AU$12.02 Million | +69.17% |
| Other Comprehensive Income | AU$-13.15K | -0.08% |
| Other Changes | AU$12.12 Million | +69.75% |
| Total Change | AU$- | -10.95% |
Book Value vs Market Value Analysis
This analysis compares Universal Biosensors Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.22x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.22x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | AU$0.29 | AU$0.01 | x |
| 2007-12-31 | AU$0.46 | AU$0.01 | x |
| 2008-12-31 | AU$0.31 | AU$0.01 | x |
| 2009-12-31 | AU$0.32 | AU$0.01 | x |
| 2010-12-31 | AU$0.30 | AU$0.01 | x |
| 2011-12-31 | AU$0.22 | AU$0.01 | x |
| 2012-12-31 | AU$0.25 | AU$0.01 | x |
| 2013-12-31 | AU$0.17 | AU$0.01 | x |
| 2014-12-31 | AU$0.11 | AU$0.01 | x |
| 2015-12-31 | AU$0.08 | AU$0.01 | x |
| 2016-12-31 | AU$0.07 | AU$0.01 | x |
| 2017-12-31 | AU$0.07 | AU$0.01 | x |
| 2018-12-31 | AU$0.29 | AU$0.01 | x |
| 2019-12-31 | AU$0.26 | AU$0.01 | x |
| 2020-12-31 | AU$0.21 | AU$0.01 | x |
| 2021-12-31 | AU$0.16 | AU$0.01 | x |
| 2022-12-31 | AU$0.13 | AU$0.01 | x |
| 2023-12-31 | AU$0.09 | AU$0.01 | x |
| 2024-12-31 | AU$0.06 | AU$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Universal Biosensors Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -81.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -226.65%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.49x
- Recent ROE (-81.97%) is below the historical average (-24.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -7.95% | -110.95% | 0.07x | 1.08x | AU$-6.65 Million |
| 2007 | -14.00% | -649.93% | 0.02x | 1.06x | AU$-14.41 Million |
| 2008 | -24.63% | -263.23% | 0.08x | 1.12x | AU$-16.87 Million |
| 2009 | 2.79% | 6.49% | 0.39x | 1.09x | AU$-3.70 Million |
| 2010 | -14.00% | -36.36% | 0.34x | 1.14x | AU$-11.33 Million |
| 2011 | -41.95% | -99.97% | 0.33x | 1.29x | AU$-18.19 Million |
| 2012 | -23.19% | -30.80% | 0.60x | 1.25x | AU$-13.07 Million |
| 2013 | -39.19% | -77.10% | 0.28x | 1.84x | AU$-14.60 Million |
| 2014 | -47.19% | -97.76% | 0.20x | 2.41x | AU$-11.29 Million |
| 2015 | -49.61% | -39.20% | 0.37x | 3.39x | AU$-7.90 Million |
| 2016 | 9.43% | 6.64% | 0.38x | 3.77x | AU$-75.15K |
| 2017 | -5.99% | -3.04% | 0.54x | 3.62x | AU$-2.04 Million |
| 2018 | 74.13% | 54.08% | 0.99x | 1.38x | AU$32.50 Million |
| 2019 | -10.68% | -70.26% | 0.11x | 1.38x | AU$-9.39 Million |
| 2020 | -20.19% | -239.40% | 0.06x | 1.48x | AU$-11.46 Million |
| 2021 | -37.31% | -178.30% | 0.13x | 1.61x | AU$-13.06 Million |
| 2022 | -102.92% | -593.48% | 0.10x | 1.77x | AU$-29.46 Million |
| 2023 | -34.56% | -101.64% | 0.22x | 1.54x | AU$-8.69 Million |
| 2024 | -81.97% | -226.65% | 0.24x | 1.49x | AU$-15.98 Million |
Industry Comparison
This section compares Universal Biosensors Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $14,750,885
- Average return on equity (ROE) among peers: -315.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Universal Biosensors Inc (UBI) | AU$7.08 Million | -7.95% | 1.11x | $1.49 Million |
| 4DMEDICAL Ltd (4DX) | $926.64K | -85.93% | 0.18x | $1.03 Billion |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $2.37 Million |
| Aroa Biosurgery Ltd (ARX) | $-22.65 Million | 0.00% | 0.00x | $92.74 Million |
| Atomo Diagnostics Ltd (AT1) | $34.48 Million | -26.73% | 0.05x | $8.96 Million |
| Control Bionics Ltd (CBL) | $6.09 Million | -15.97% | 0.04x | $4.98 Million |
| Cardiex Ltd (CDX) | $3.03 Million | -101.61% | 0.73x | $4.25 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $13.08 Million |
| Cochlear Ltd (COH) | $75.42 Million | 53.19% | 1.13x | $7.01 Billion |
| Cleo Diagnostics Ltd (COV) | $5.83 Million | -68.54% | 0.19x | $23.47 Million |
| Conneqt Health Limited (CQT) | $633.50K | -2871.98% | 13.72x | $4.66 Million |